SMAD2 mRNA expression is upregulated in fibrosing interstitial lung diseases (ILDs)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F15%3A%230001173" target="_blank" >RIV/00064190:_____/15:#0001173 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1183/13993003.congress-2015.PA934" target="_blank" >http://dx.doi.org/10.1183/13993003.congress-2015.PA934</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1183/13993003.congress-2015.PA934" target="_blank" >10.1183/13993003.congress-2015.PA934</a>

Jazyk výsledku

angličtina

Název v původním jazyce

SMAD2 mRNA expression is upregulated in fibrosing interstitial lung diseases (ILDs)

Popis výsledku v původním jazyce

Abstract ILDs are heterogenous group of diseases with different extent of inflammation and fibrosis. Fibrotic types of ILDs(IPF and NSIP) are associated with the worst prognosis. In pathogenesis of fibroproduction dysregulation of TGFbeta among others probably plays significant role. Methods: 11 patients with hypersensitivity pneumonitis(HP), 15 patients with fibrosing ILDs(IPF and NSIP) and 8 patients with connective tissue diseases (CTD) were enrolled into the prospective study. All patients underwent bronchoscopy with transbronchial biopsy during the diagnostic programme. After isolation of mRNA from lung biopsies, mRNA expression of F2RL1, GPER, IL4R, IL 13, SMAD 2, SMAD 3, TGF beta, TNF alpha, TSLP, VEGFA and YY1 were measured using TLDA cards. CT scans at the time of diagnosis were scored according to Gay S. procedure and alveolar and interstitial score was set. Groups of patients were compared using Cruscal Wallis test and relation between HRCT score and mRNA expression were estimated by Spearman correlation coefficient. Results: RNA expression of SMAD 2 was significantly higher in the group of fibrosing ILDs(median:1.90) comparing to HP(median:0.99, p=0.008) and CTD group(med.:0.98,p=0.02). Differences in other measured expressions between groups didn't reach statistical significance. Negative correlation has been found between alveolar score and SMAD 2 in all patients (p: 0.016). Conclusion: We have observed upregulated expression of SMAD 2 mRNA in the group of fibrosing ILDs. Moreover the SMAD values negatively correlated with alveolar score. We hypothesise that SMAD 2 might be used as a biomarker of fibroproliferative healing in ILDs.

Název v anglickém jazyce

SMAD2 mRNA expression is upregulated in fibrosing interstitial lung diseases (ILDs)

Popis výsledku anglicky

Abstract ILDs are heterogenous group of diseases with different extent of inflammation and fibrosis. Fibrotic types of ILDs(IPF and NSIP) are associated with the worst prognosis. In pathogenesis of fibroproduction dysregulation of TGFbeta among others probably plays significant role. Methods: 11 patients with hypersensitivity pneumonitis(HP), 15 patients with fibrosing ILDs(IPF and NSIP) and 8 patients with connective tissue diseases (CTD) were enrolled into the prospective study. All patients underwent bronchoscopy with transbronchial biopsy during the diagnostic programme. After isolation of mRNA from lung biopsies, mRNA expression of F2RL1, GPER, IL4R, IL 13, SMAD 2, SMAD 3, TGF beta, TNF alpha, TSLP, VEGFA and YY1 were measured using TLDA cards. CT scans at the time of diagnosis were scored according to Gay S. procedure and alveolar and interstitial score was set. Groups of patients were compared using Cruscal Wallis test and relation between HRCT score and mRNA expression were estimated by Spearman correlation coefficient. Results: RNA expression of SMAD 2 was significantly higher in the group of fibrosing ILDs(median:1.90) comparing to HP(median:0.99, p=0.008) and CTD group(med.:0.98,p=0.02). Differences in other measured expressions between groups didn't reach statistical significance. Negative correlation has been found between alveolar score and SMAD 2 in all patients (p: 0.016). Conclusion: We have observed upregulated expression of SMAD 2 mRNA in the group of fibrosing ILDs. Moreover the SMAD values negatively correlated with alveolar score. We hypothesise that SMAD 2 might be used as a biomarker of fibroproliferative healing in ILDs.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FC - Pneumologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology.

ISSN

0903-1936

e-ISSN

—

Svazek periodika

46

Číslo periodika v rámci svazku

Suppl. 59

Stát vydavatele periodika

DK - Dánské království

Počet stran výsledku

3

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—